only with
Strides Pharma Science Ltd.
Strides Pharma Scien
Strides Pharma Science Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹106.64 Cr.
| EX-Date | Purpose |
|---|---|
| 27 05 2021 | Audited Results |
| 06 08 2021 | Quarterly Results |
| 10 11 2021 | Quarterly Results |
| 28 01 2022 | Quarterly Results |
| 10 02 2022 | Quarterly Results (Revised) |
| 24 05 2022 | Quarterly Results & Dividend & Audited Results |
| 25 07 2022 | Inter alia, to consider and approve Intimation of raising of funds by way of issuance of Non-Convertible Debentures under Regulation 29 of SEBI Listing Regulations. |
| 29 07 2022 | Quarterly Results |
| 14 11 2022 | Quarterly Results |
| 24 01 2023 | Quarterly Results |
| 25 05 2023 | Final Dividend & Audited Results |
| 02 08 2023 | Quarterly Results |
| 25 09 2023 | Scheme of Arrangement |
| 30 10 2023 | Quarterly Results |
| 30 01 2024 | Quarterly Results |
| 24 10 2024 | Quarterly Results |
| 30 01 2025 | Quarterly Results |
| 22 05 2025 | Final Dividend & Audited Results |
| 29 07 2025 | Quarterly Results |
| 31 10 2025 | Quarterly Results |
| 30 01 2026 | Quarterly Results |
| 18 05 2026 | Final Dividend & Audited Results |
News
Strides Pharma’s arm inks pact with Sandoz to acquire branded generics portfolio in SSA
The initial consideration for the transaction is $12 million, payable at closing
Strides Pharma’s arm acquires Neviton Softech
Neviton and Arco Lab synergize their strengths and enables Arco Lab to offer better knowledge-based and IT services
Strides Pharma’s arm gets USFDA inspection closure report for New York Formulations Facility
The successful closure of inspection further strengthens the company’s U.S. business and near-term growth prospects
USFDA concludes cGMP inspection at formulations facility of Strides Pharma’s arm
At the conclusion of the inspection, the USFDA has issued a Form 483 with four observations
Strides Pharma Science’s arm enters into strategic product development partnership with Kenox
Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications
Strides Pharma Science’s arm acquires identified ANDAs from Nostrum Laboratories, Inc, USA
Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months
Strides Pharma Science’s arm incorporates wholly owned subsidiary
Pivot Path shall focus on life sciences and manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities
Strides Pharma Science’s board approves demerger of identified business of Arco Lab
Arco Lab will incorporate the NewCo to facilitate the proposed demerger
Strides Pharma Science’s arm gets USFDA’s approval for Acetaminophen and Ibuprofen Tablets
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Strides Pharma Science’s arm to acquire balance 30% stake in Strides Pharma International AG
The acquisition marks a significant milestone in Strides’ expansion efforts, further strengthening its position in the region
Strides Pharma Science gets nod to invest Rs 1.61 crore in AMPIN C&I
This project will facilitate harnessing solar energy at the company’s Alathur facility
Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs
The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry
Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug Prozac Tablets of Eli Lilly
USFDA completes cGMP inspection at Chennai formulations facility of Strides Pharma Science’s arm
The inspection closed with two observations
Strides Pharma Science’s arm receives USFDA’s approval for Gabapentin Tablets
The Gabapentin tablets will be manufactured at the company’s facility in Puducherry
Strides Pharma Science’s arm receives USFDA’s approval for Pregabalin Capsules
The product is bioequivalent and therapeutically equivalent to the RLD, Lyrica capsules of Upjohn US
Strides Pharma Science’s arm acquires additional stake in Neviton Softech
With the said acquisition, Arco Lab holds 50% stake in Neviton
Strides Pharma Science to invest in AMP-6, AMP-8
The Management Committee of the Board of Directors of the Company in its meeting held on January 2, 2024, has approved the same
Strides Pharma Science’s arm gets USFDA’s nod for Generic Suprep Bowel Prep Kit
The Product has a market size of $143 Million per IQVIA. The Product will be manufactured at the company’s facility in Bengaluru
Strides Pharma Science’s arm gets USFDA’s nod for Levetiracetam Oral Solution
The product will be manufactured at the company’s facility in Bengaluru
Strides Pharma’s arm to sell manufacturing facility for $15 million
Proceeds from the transaction will be utilized for debt reduction
Strides Pharma Science’s arm gets USFDA’s approval for EET tablets
The product will be manufactured at the company’s facility in Bengaluru
Strides Pharma Science to demerge CDMO, soft gelatin biz into separate entity
It is proposed to combine the identified CDMO business of Strides and the identified CDMO business of Steriscience under Stelis
Strides Pharma’s arm gets USFDA’s tentative nod for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets
The Product will be manufactured at the company’s facility in Bengaluru
Strides Pharma Science’s arm gets tentative approval for Dolutegravir 50mg tablets
The company has set a target to launch around 60 new products over three years in the US
Strides Pharma Science’s arm gets USFDA’s approval for Sevelamer Carbonate for Oral Suspension
The approval completes the company’s Sevelamer Carbonate portfolio
Strides Pharma Science gets nod to acquire 100% stake in Strides Pharma Services
The Board of Directors of the company at their meeting held on September 7, 2023, has approved the same
Strides Pharma Science’s arm gets USFDA’s nod for Mycophenolate Mofetil for Oral Suspension
The approval bolsters the company’s Mycophenolate Mofetil portfolio, which already includes numerous products in which the company is a market leader
Strides Pharma Science’s biologics arm enters into binding term sheet with Syngene International
Syngene shall acquire Unit 3 on a slump sale basis for a gross value of Rs 7,020 million
Strides Pharma Science gets EIR from USFDA for Puducherry manufacturing facility
The USFDA has classified the facility from Official Action Indicated to Voluntary Action Indicated
Strides Pharma Science enters into strategic partnership with Orbicular
Strides will commercialize these nasal sprays across the markets using its commercial engine in the US, Europe, and several other markets
USFDA issues EIR to Strides Pharma Science’s Bangalore facility
The Company’s flagship facility was inspected by the USFDA between December 5 and 9, 2022
Strides Pharma Science’s arm receives EIR from USFDA
This Abbreviated Quality System Inspection Technique drug preapproval on-site inspection was specifically conducted by the USFDA
Strides Pharma Science’s arm’s CDMO partner gets nod for key ANDA from USFDA
Stelis will manufacture and commercially supply the product to its CDMO partner from its flagship facility in Bangalore, India
Strides Pharma Science’s arm gets AUD 94 million as deferred consideration for sale of Australian operations
The proceeds will be utilized for deleveraging the balance sheet
Strides Pharma Science’s arm gets USFDA approval for Potassium Chloride Oral Solution
The approval further strengthens the Potassium Chloride franchise for the company which now comprises of Extended-Release Capsules, Extended-Release Tablets, Powder for Oral Solutions and Oral Solutions
Strides Pharma’s arm receives EIR from USFDA for Drug Products facility in Bengaluru
This outcome for the DP facility comes after the USFDA on-site PAI at Stelis flagship manufacturing facility for several product submissions by the partners to the agency
Strides Pharma Science’s arm recalls 1,032 bottles of Prednisone tablets
As per the USFDA, the company is recalling the affected lot due to presence of foreign tablet
USFDA completes inspection at Strides Pharma Science’s Singapore facility
The inspection was completed successfully with Zero 483 observations
Strides Pharma’s arm gets USFDA’s approval for Cyclosporine Softgel Capsules
Strides is the first Indian company to get approval for the product
Strides Pharma Science to raise funds through NCDs
A meeting of the Committee of Directors is scheduled to be held on July 25, 2022, inter alia, to consider and approve the same
Strides Pharma Science’s arm gets USFDA’s nod for Ibuprofen Oral Suspension
The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market
Strides Pharma Science’s arm gets USFDA’s nod for Ibuprofen Oral Suspension
The US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL is approximately $66 million